Method for producing umbilcal cord blood-derived stem cell with enhanced efficacy

A method for enhancing efficacy of an umbilical cord blood-derived mesenchymal stem cell, the method comprising

• culturing the umbilical cord blood-derived mesenchymal stem cell on a poly(vinylidene fluoride) (PVDF) membrane in the form of a film formed by electrospinning, the PVDF membrane having a surface coated with fibronectin,
• wherein enhancing efficacy of a stem cell includes at least one of increase in growth factor expression, regulation of expression of a factor involved in a signaling pathway, a reduction in size of stem cells, improvement in proliferation ability, improvement in differentiation potency, improvement in immunoregulatory ability, improvement in migration ability, improvement in engraftment capacity, improvement in angiogenic potential, increase in secretion of bio-nanoparticles, decrease in immunogenicity, increase in stemness, suppression of cell viability reduction, and decrease in cellular senescence,
• wherein the enhancement of efficacy of the stem cell comprises:
• (a) an increase in expression of at least one of EFNA1 (Ephrin-A1), ADAM8 (ADAM metallopeptidase domain 8), ANGPTL4 (Angiopoietin-like 4), ANGPTL6 (Angiopoietin-like 6), CYP1B1 (Cytochrome P450 family 1 subfamily B member 1), APOD (Apolipoprotein D), KDR (Kinase insert domain receptor), EREG (Epiregulin), ADTRP (Androgen-dependent TFPI-regulating protein), SLC7A8 (Solute carrier family 7 member 8), ITGA11 (Integrin alpha-11), IL1B (Interleukin 1 beta), FLRT3 (Fibronectin leucine rich transmembrane protein 3), THBD (Thrombomodulin), CXCL6 (Chemokine (C-X-C motif) ligand 6), ITGB8 (Integrin beta-8), HGF (Hepatocyte growth factor), CAMKID (Calcium/calmodulin-dependent protein kinase ID), LACC1 (Laccase domain containing 1), GPR68 (G protein-coupled receptor 68), BDKRB2 (Bradykinin receptor B2), NLRC4 (NLR family CARD domain containing 4), SCN1A (Sodium voltage-gated channel alpha subunit 1), ASS1 (Argininosuccinate synthase 1), KCNAB2 (Potassium voltage-gated channel subfamily A beta member 2), SLC6A9 (Solute carrier family 6 member 9), CTSW (Cathepsin W), SYT12 (Synaptotagmin 12), TNFSF13B (Tumor necrosis factor ligand superfamily member 13B), ABCC3 (ATP binding cassette subfamily C member 3), and QPCT (Glutaminyl-peptide cyclotransferase);
• or
• (b) a decrease in expression of at least one of EPHA2 (EPH receptor A2), ESM1 (Endothelial cell-specific molecule 1), SLC7A10 (Solute carrier family 7 member 10), HES1 (Hes family bHLH transcription factor 1), WWC1 (WW and C2 domain containing 1), NEDD9 (Neural precursor cell expressed, developmentally down-regulated 9), and IL31RA (Interleukin 31 receptor A).